MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.clgc.2026.102614

Медицинская библиотека · Clinical genitourinary cancer · 2026

Quality-of-Life in CRPC Patients Treated With Enzalutamide Versus Abiraterone: Impact of Standard and Modified Dosing.

Tatarano Shuichi, Izumi Kouji, Enokida Hideki, Shima Takashi, Kato Yuki, Mita Koji, Okamura Takehiko, Inoue Shogo, Hoshi Seiji, Tanaka Nobumichi, Kamiyama Manabu, Chikazawa Ippei, Kawai Noriyasu, Hashimoto Kohei, Fukagai Takashi, Shigehara Kazuyoshi, Takahara Shizuko, Mizokami Atsushi

СтатьяРандомизированное исследованиеМногоцентровое исследованиеСравнительное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Head-to-head comparisons between enzalutamide (ENZ) and abiraterone plus prednisolone (ABI) have shown comparable survival benefits in patients with castration-resistant prostate cancer (CRPC). However, the quality of life (QoL) associated with these agents has not been directly compared. We conducted a sub-analysis to evaluate longitudinal changes in QoL within each treatment arm.

METHODS

The ENABLE study for PCa, an investigator-initiated, multicenter, randomized controlled trial, was performed. Patient-reported QoL was assessed using the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire, including subscales of physical, social, emotional, and functional well-being, at predefined timepoints.

RESULTS

A total of 89 patients were included in each arm, with 76 (ENZ) and 74 (ABI) responding to the questionnaires. There were no significant differences in time to prostate-specific antigen progression or overall survival between arms (P = .1694 and P = .6306). ENZ did not change the total FACT-G score during the treatment course (P = .9585), whereas ABI significantly and gradually deteriorated it (P = .0003). In the ABI arm, the standard dose (1000 mg/d) significantly deteriorated the total FACT-G score (n = 55, P = .0003), while the modified dose (≤ 750 mg/d) did not (n = 15, P = .1816). Subscale analysis showed that ENZ did not deteriorate any domains, whereas ABI significantly worsened social and functional well-being (P = .0128 and P = .0006, respectively). Further analysis revealed that the modified dose of ABI did not deteriorate social or functional well-being (P = .6549 and P = .5837, respectively) while the standard dose significantly worsened both (P = .0010 and P < .0001, respectively).

CONCLUSIONS

ABI deteriorated QoL over time, with the standard dose being the main contributor. The modified dose of ABI may represent a better treatment option to preserve QoL.

Для цитирования: Tatarano Shuichi, Izumi Kouji, Enokida Hideki, Shima Takashi, Kato Yuki, Mita Koji, Okamura Takehiko, Inoue Shogo, Hoshi Seiji, Tanaka Nobumichi, Kamiyama Manabu, Chikazawa Ippei, Kawai Noriyasu, Hashimoto Kohei, Fukagai Takashi, Shigehara Kazuyoshi, Takahara Shizuko, Mizokami Atsushi. Quality-of-Life in CRPC Patients Treated With Enzalutamide Versus Abiraterone: Impact of Standard and Modified Dosing.. Clinical genitourinary cancer. 2026. DOI: 10.1016/j.clgc.2026.102614.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.